Skip to main content

Table 1 Summary of pharmacokinetic profiles for omalizumab [4, 5], mepolizumab [7, 10, 16] and reslizumab [6, 9]

From: The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review

 

Omalizumab

Mepolizumab

Reslizumab

Route

SC

SC

IV

IV

Absolute bioavailability

100%

100%

–

–

Tmax

7–8 days

4–8 days

End of infusion

End of infusion

Vd

78 mL/kg

51 mL/kg

55–85 mL/kg

≈5 L

CLS

2.4 mL/kg/day

3.1 mL/kg/day

1.9–3.3 mL/kg/day

≈7 mL/hour

t½

26 days

16–22 days

≈20 days

≈24 days

  1. CLS systemic clearance, IV intravenous, PK pharmacokinetics, SC subcutaneous, t½ elimination half-life, Tmax time to Cmax, Vd volume of distribution